What Happened? Shares of biotech company Regeneron (NASDAQ:REGN) jumped 3.3% in the morning session after the company ...

Moving on, Regeneron’s second-quarter report was largely positive. Total revenues of $3.68 billion (up 4% YoY) beat analyst ...

What Happened? A number of stocks jumped in the afternoon session after positive inflation data fueled hopes for an interest ...

On Friday, Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) reported second-quarter adjusted earnings of $12.89 per share, up 12% ...

Regeneron (REGN) came out with quarterly earnings of $12.89 per share, beating the Zacks Consensus Estimate of $8.03 per ...

Return on Equity (ROE): Regeneron Pharmaceuticals's financial strength is reflected in its exceptional ROE, which exceeds ...

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is one of the Most Undervalued Long Term Stocks to Buy According to Hedge Funds ...

REGN Factor-Based Stock Analysis - Benjamin Graham June 25, 2025 — 02:07 pm EDT Written by John Reese for Validea -> ...

Viking Therapeutics ' ( VKTX 0.28%) shares could rise over the next year by as much as 165% at the midpoint according to some ...

Second Quarter 2025 Results Key Financial Results Revenue: US$3.68b (up ...

REGENERON PHARMACEUTICALS INC (REGN) is a large-cap value stock in the Biotechnology & Drugs industry. The rating using this strategy is 86% based on the firm’s underlying fundamentals and the ...